Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use

Patent metadata

Field	Value
Publication number	US-9950005-B2
Application number	US-201514610479-A
Country	US
Kind code	B2
Filing date	Jan 30, 2015
Priority date	May 3, 2006
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

First claim

The invention claimed is:

1. A method of treating a pathological condition selected from the group consisting of a neuronal injury, a tissue injury, a surgical intervention, and any combination thereof, the method comprising delivering to a subject in need thereof a therapeutically effective amount of at least one biomembrane sealing agent comprising between 20% and 50% w/w of polyethylene glycol (PEG) and a therapeutically effective amount of at least one bioactive agent comprising magnesium, wherein the at least one biomembrane sealing agent is delivered in an injectable composition, and wherein the magnesium comprises magnesium chloride, and the PEG comprises PEG3350.

2. The method of claim 1 , wherein neuronal injury is selected from the group consisting of an injury to the central nervous system, an injury to the peripheral nervous system, an injury to the cranial nerves, an injury to the optical nerve and any combination thereof.

3. The method of claim 1 wherein the therapeutically effective amount of at least one biomembrane sealing agent and the therapeutically effective amount of at least one bioactive agent are delivered by a delivery method selected from the group consisting of an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application or deposition onto or adjacent to a site of the pathological condition, and any combinations thereof.

4. The method of claim 1 wherein the method is the intravenous administration.

5. The method of claim 1 , wherein the at least one biomembrane agent and at least one bioactive agent are delivered independently of each other.

6. The method of claim 1 , wherein the at least one biomembrane sealing agent and the at least one bioactive agent are combined before the step of delivering the at least one biomembrane sealing agent and the at least one bioactive agent to the subject in need thereof.

7. The method of claim 1 , wherein the at least one biomembrane sealing agent or the at least one bioactive agent are delivered from an implant.

8. The method of claim 1 wherein the at least one biomembrane sealing agent or the at least one bioactive agent are delivered from a pump.

9. The method of claim 1 , wherein at least one compound is delivered prior to an occurrence of the pathological condition, said one compound selected from the group consisting of the at least one biomembrane sealing agent and the at least one bioactive agent.

10. The method of claim 1 , wherein the composition is incapable of forming a gel.

11. A method of treating a pathological condition, selected from the group consisting of a neuronal injury, a tissue injury, a surgical intervention, and any combination thereof, the method comprising delivering to a subject in need thereof a therapeutically effective amount of at least one biomembrane sealing agent comprising between 20% and 50% w/w of polyethylene glycol (PEG) and a therapeutically effective amount of at least one magnesium compound, wherein the at least one biomembrane sealing agent is delivered in an injectable composition, wherein the at least one magnesium compound comprises magnesium chloride, and the PEG comprises PEG3350.

12. The method of claim 11 , wherein the neuronal injury is selected from the group consisting of an injury to the central nervous system, an injury to the peripheral nervous system, an injury to the cranial nerves, an injury to the optical nerve and any combination thereof.

13. The method of claim 11 wherein the therapeutically effective amount of at least one biomembrane sealing agent and the therapeutically effective amount of at least one magnesium compound are delivered by a delivery method selected from the group consisting of an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application or deposition onto or adjacent to a site of the pathological condition, and any combinations thereof.

14. The method of claim 11 wherein the method is the intravenous administration.

15. The method of claim 11 wherein the injectable composition is incapable of forming a gel.

16. The method of claim 1 , wherein the method further comprises mixing an antioxidant with the at least one biomembrane sealing agent.

17. The method of claim 11 , wherein the method further comprises mixing an antioxidant with the at least one biomembrane sealing agent.

18. The method of claim 1 , wherein the at least one biomembrane sealing agent comprising 20% w/w of the PEG.

19. The method of claim 1 , wherein the at least one biomembrane sealing agent comprising 30% w/w of the PEG.

Assignees

• Warsaw Orthopedic Inc

Inventors

• Roy Josee
• Mckay William F
• Marx Jeffrey C

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K33/06 Primary

  Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} · CPC title